Antibodies to the Plasmodium falciparum proteins MSPDBL1 and MSPDBL2 opsonise merozoites, inhibit parasite growth and predict protection from clinical malaria
- Chiu, CY; Hodder, AN; Lin, CS; Hill, DL; Li Wai Suen, CS; Schofield, L; Siba, PM; Mueller, I; Cowman, AF; Hansen, DS;
Publication Year 2015-08-01, Volume 212, Issue #3, Page 406-415
- Journal Title
- J Infect Dis
- Publication Type
- Journal Article
- Increasing evidence suggests that antibodies against merozoite surface proteins play an important role in clinical immunity to malaria. Two unusual members of the Merozoite surface protein (MSP)-3 family named MSPDBL1 and MSPDBL2 have been shown to be extrinsically associated to MSP-1 on the parasite surface. In addition to a Secreted Polymorphic Antigen associated with Merozoite (SPAM) domain characteristic of MSP-3 family members, they also contain Duffy Binding Like (DBL) domain and were found to bind to erythrocytes suggesting that they play a role in parasite invasion. Antibody responses to these proteins were investigated in a treatment-re-infection study conducted in an endemic area of Papua New Guinea (PNG) to determine their contribution to naturally acquired immunity. Antibodies to the SPAM domains of MSPDBL1 and MSPDBL2 as well as the DBL domain of MSPDBL1 were found to be associated with protection from P. falciparum clinical episodes. Moreover, affinity purified anti-MSPDBL1 and MSPDBL2 were found to inhibit in vitro parasite growth and had strong merozoite opsonising capacity, suggesting that protection targeting these antigens results from at least 2 different effector mechanisms. Together these results indicate that MSPDBL1 and MSPDBL2 are important targets of naturally acquired immunity and might constitute potential vaccine candidates.
- WEHI Research Division(s)
- Infection And Immunity; Population Health And Immunity
- Publisher's Version
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2015-02-05 03:45:50Last Modified: 2019-04-01 09:14:43